|
CSTF2T expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.78634884662188E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.28369578592469E-11 |
| Normal-vs-Stage2 |
3.57380000000074E-05 |
| Normal-vs-Stage3 |
3.01949576453353E-11 |
| Normal-vs-Stage4 |
9.60032053853865E-12 |
| Stage1-vs-Stage2 |
6.576600E-01 |
| Stage1-vs-Stage3 |
6.435900E-02 |
| Stage1-vs-Stage4 |
4.260800E-03 |
| Stage2-vs-Stage3 |
1.141990E-01 |
| Stage2-vs-Stage4 |
1.096070E-02 |
| Stage3-vs-Stage4 |
1.936610E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.6296300126869E-13 |
| Normal-vs-AfricanAmerican |
2.12209999999047E-05 |
| Normal-vs-Asian |
1.55698999999565E-05 |
| Caucasian-vs-AfricanAmerican |
8.436200E-01 |
| Caucasian-vs-Asian |
3.167800E-01 |
| AfricanAmerican-vs-Asian |
4.017200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.02480312703346E-11 |
| Normal-vs-Female |
2.90223400867262E-12 |
| Male-vs-Female |
2.950600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.77589992395633E-10 |
| Normal-vs-Age(41-60Yrs) |
1.01889607861949E-11 |
| Normal-vs-Age(61-80Yrs) |
3.913099844155E-10 |
| Normal-vs-Age(81-100Yrs) |
7.055500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.900200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.840200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.085600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.809200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.728800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.274800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.444200E-02 |
| Classical-VS-Follicular |
3.078200E-02 |
| Classical-VS-Other |
2.349000E-01 |
| Classical-VS-Normal |
1.12239995075925E-10 |
| Tall-VS-Follicular |
5.062200E-01 |
| Tall-VS-Other |
9.297400E-01 |
| Tall-VS-Normal |
1.90159998858519E-09 |
| Follicular-VS-Other |
6.990600E-01 |
| Follicular-VS-Normal |
1.14260001460309E-09 |
| Other-VS-Normal |
2.342700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.94629987074302E-10 |
| Normal-vs-N1 |
3.21439541650648E-11 |
| N0-vs-N1 |
1.397550E-02 |
|
|
